# Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

> **NCT01300156** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 37 (estimated)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** Oxaliplatin-based chemotherapy (ESHAOx)

## Key facts

- **NCT ID:** NCT01300156
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-02
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2011-02-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300156, "Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01300156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*